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Abstract
Aims: De-escalation trials are challenging and sometimes may fail due to poor recruitment. The OPTIMA Prelim randomised controlled trial (ISRCTN42400492)
randomised patients with early stage breast cancer to chemotherapy versus ‘test-directed’ chemotherapy, with a possible outcome of no chemotherapy, which
could confer less treatment relative to routine practice. Despite encountering challenges, OPTIMA Prelim reached its recruitment target ahead of schedule. This
study reports the root causes of recruitment challenges and the strategies used to successfully overcome them.
Materials and methods: A mixed-methods recruitment intervention (QuinteT Recruitment Intervention) was used to investigate the recruitment difficulties and
feedback findings to inform interventions and optimise ongoing recruitment. Quantitative site-level recruitment data, audio-recorded recruitment appoint-
ments (n ¼ 46), qualitative interviews (n ¼ 22) with trialists/recruiting staff (oncologists/nurses) and patient-facing documentation were analysed using
descriptive, thematic and conversation analyses. Findings were triangulated to inform a ‘plan of action’ to optimise recruitment.
Results: Despite best intentions, oncologists’ routine practices complicated recruitment. Discomfort about deviating from the usual practice of recommending
chemotherapy according to tumour clinicopathological features meant that not all eligible patients were approached. Audio-recorded recruitment appoint-
ments revealed how routine practices undermined recruitment. A tendency to justify chemotherapy provision before presenting the randomised controlled trial
and subtly indicating that chemotherapy would be more/less beneficial undermined equipoise and made it difficult for patients to engage with OPTIMA Prelim.
To tackle these challenges, individual and group recruiter feedback focussed on communication issues and vignettes of eligible patients were discussed to
address discomforts around approaching patients. ‘Tips’ documents concerning structuring discussions and conveying equipoise were disseminated across sites,
together with revisions to the Patient Information Sheet.Author for correspondence: C. Conefrey, Population Health Sciences, University of Bristol, Bristol, UK.
E-mail address: carmel.conefrey@bristol.ac.uk (C. Conefrey).
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C. Conefrey et al. / Clinical Oncology 32 (2020) 382e389 383Conclusions: This is the first study illuminating the tension between oncologists’ routine practices and recruitment to de-escalation trials. Although time and
resources are required, these challenges can be addressed through specific feedback and training as the trial is underway.
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Multiparameter tumour gene expression assays have
driven new approaches to adjuvant chemotherapy
decision-making for breast cancer [1e3]. The UK’s National
Institute for Health and Care Excellence has approved the
use of several multi-parameter assays (MPAs) to guide
adjuvant chemotherapy decisions in patients with oes-
trogen receptor-positive, human epidermal growth factor
receptor 2-negative lymph node-negative breast cancer.
Although there is potential to extend this recommendation
to node-positive patients, the National Institute for Health
and Care Excellence has called for robust randomised
controlled trial (RCT) evidence to inform future guidance
[4]. For more than 50 years, RCTs have been driving
important developments in the treatment of breast cancer
[5e7], but recruitment issues have threatened the timely
and successful completion of trials [8,9]. This is particularly
true of de-escalation of treatment studies, which have
come to the fore in early breast cancer research in recent
years [10]. Reported obstacles have included logistical is-
sues, lack of eligible patients, limited research resources
and patient preferences for/against treatments [11].
Research has revealed a number of challenges for re-
cruiters, including the emotional burden of recruitment,
lack of equipoise and reconciling the roles of clinician and
researcher [12,13].
The Optimal Personalised Treatment of early breast
cancer using Multi-parameter Analysis (OPTIMA) trial
[14,15] is a UK-based multicentre clinical trial that ran-
domises patients to adjuvant chemotherapy (current care)
versus ‘test-directed’ adjuvant chemotherapy or ‘no
chemotherapy’. OPTIMA is designed to show the non-
inferiority of this approach to patient outcome, particu-
larly for those with node-positive disease. OPTIMA Prelim
was the feasibility phase of the study and was designed to
show the acceptability of a large-scale trial of MPA-
directed treatment to patients and clinicians. An over-
view of OPTIMA Prelim is reported in full elsewhere
[15,16] and included in the Supplementary Material. The
OPTIMA Prelim trial management group (TMG) antici-
pated that recruitment would be difficult, as many pa-
tients who would be offered chemotherapy in current UK
practice, would be allocated to ‘no chemotherapy’ within
the trial. The TMG therefore integrated the ‘QuinteT
Recruitment Intervention’ (QRI) [17] into the RCT protocol.
This is a complex intervention that aims to identify and
understand sources of recruitment difficulty rapidly, and
then develop strategies to address these throughout the
remainder of the trial. An evaluation of the effectiveness
of the QRI approach using before and after data for severaltrials, including OPTIMA Prelim, has been published
elsewhere [18].
This paper reports on the sources of recruitment diffi-
culty in this challenging trial and the specific strategies
implemented to try to overcome these.Materials and methods
Design
This paper reports a mixed-methods study using the QRI
[17,19] to understand and address recruitment issues. The
QRI consisted of two iterative phases. Phase 1 aimed to
understand recruitment obstacles rapidly, using mixed
(predominantly qualitative) methods. Phase 2 involved
working collaboratively with the chief investigator and
TMG to devise and deliver tailored strategies to address
recruitment difficulties, based on evidence from phase 1.
The QRI was integratedwithin the study protocol; ethical
approval was granted by the South East CoasteSurrey
Research Ethics Committee (12/LO/0515, 22 June 2012).QuinteT Recruitment Intervention phase 1: understanding
recruitment obstacles
Phase 1 began when recruitment had started. All sites
open at the time (n ¼ 25) were invited to take part; nine
agreed to participate in one or more aspects of the data
collection discussed below.
Key informants, including oncologists, research nurses
and TMG members, were purposefully sampled for inter-
view based on their role in overseeing or conducting
recruitment. In total, 32 staff were invited to participate in
in-depth semi-structured interviews about their perspec-
tives on recruitment. Interviews were conducted face-to-
face or via telephone (by LR and JLD) and lasted between
40 and 90 min. Research nurses were also approached to
take part in shorter, structured interviews regarding the
operation of recruitment processes at their sites. Sampling
for interviews concluded when data saturationwas reached
(i.e. when no new issues arose from two consecutive
interviews).
Recruiting staff (oncologists and research nurses) were
asked to routinely audio-record discussions concerning
OPTIMA Prelim with eligible patients (‘recruitment ap-
pointments’), including when they accepted or declined
trial participation. Initial verbal and subsequent written
patient consent was obtained for all audio-recordings.
All interviews and audio-recorded appointments were
analysed thematically using the constant comparative
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In addition, techniques adapted from conversation analysis
[21] were used to examine the structure and sequencing of
interactions. All transcripts of interviews/appointments
were analysed by one researcher using the above tech-
niques (LR). To enhance reliability, another researcher (SP)
analysed 10% of interviews and appointments in the early
stages of data collection, with semantic differences in cod-
ing discussed and resolved. Going forwards, key findings
and interpretations from the analysis were interrogated by
the study team (LR, SP, JD) through testing claims with raw
data and discussing in regular meetings. Finally, a new
researcher (CC) joined the team once data collection was
complete and listened to all audio-recorded consultations
and reviewed interview transcripts/coding, with a view to
agreeing the core messages pertaining to this paper with LR
and JD.
The data collection techniques were supplemented with
content analysis of patient-facing documentation and
descriptive analyses of recruitment screening logs.
Screening logs were regularly assessed to summarise the
numbers of patients recorded as eligible and the proportion
of those who accepted/declined an invitation to participate.
Figures were compared over time and across sites.
QuinteT Recruitment Intervention phase 2: developing and
delivering a ‘Plan of Action’ to optimise recruitment
Data and emerging findings from the analyses were
considered in tandem to triangulate data and crystallise the
key issues that seemed to be undermining recruitment.
These issues were reported to the chief investigator/TMG
and informed a ‘plan of action’ to optimise recruitment. A
statistical evaluation of the impact of these strategies on
recruitment has been reported elsewhere [18].Results
Phase 1: understanding recruitment obstacles
Early in the recruitment phase, 14 semi-structured in-
terviews were conducted with TMG members and oncolo-
gists from six sites and eight research nurses took part in
structured interviews. The interviews were conducted with
staff from sites considered ‘mid-range’ in terms of recruit-
ment rates (recruiting 0.32e1.85 patients per month,
compared with a range of 0e2.20 in the overall trial). Be-
tween November 2012 and January 2014, 46 appointments
were audio-recorded, involving 11 oncologists and 29 pa-
tients (Table 1). The audio-recordings and interviews were
obtained from recruiting sites from Scotland and the South
West, South East and Midlands regions of England.
Challenges to recruitment
Analysis of interviews highlighted that oncologists were
generally very committed to OPTIMA’s endeavour of better
targeting which patients benefited from chemotherapy
provision and often emphasised the need for evidence-based approaches to reduce the burden of over-treatment.
Despite this enthusiasm, difficulties arose at two key
points of the recruitment process: approaching eligible
patients and discussing OPTIMA Prelim in recruitment
appointments.
Approaching eligible patients. Discomfort with aspects of
the eligibility criteria, coupled with some hesitancy
about the accuracy of multiparameter testing resulted in
some eligible patients not being approached about trial
participation. Oncologists and other members of the
multidisciplinary team (MDT) had variable thresholds of
comfort regarding different aspects of the eligibility
criteria associated with risk of recurrence. This was
particularly evident in relation to patients’ nodal status.
The eligibility criteria allowed for patients with up to
nine involved lymph nodes to be included in the study,
but oncologists’ individual thresholds for permitted
nodal involvement varied.
The only thing that surprised me with the criteria is the
lymph node status; one, because it’s almost ingrained in our
practice and certainly as oncology trainees as we go
through doing the exams and so on, that lymph node pos-
itivity is a risk factor for a recurrence, and that those pa-
tients who are highest risk, benefit from chemotherapy
most. (Oncologist Site 4)
Some oncologists took into account tumour character-
istics and criteria not specified in the trial protocol in their
judgements of who to approach for the trial. These were
criteria that they would usually consider in treatment de-
cisions in routine practice where MPA testing was not
normally available. For example, some oncologists were
reluctant to approach patients with grade 3 tumours, on the
basis that they felt that these individuals would require
chemotherapy.
I think people feel very uncomfortable about letting heavily
node positive grade 3 disease [into the trial] . there’s
something about - they strongly feel those patients need
chemo, and the idea that they might go into a trial where
they’re not being given chemo makes them feel very un-
comfortable. (Oncologist Site 2)
Assessments about patients’ emotional state also factored
into decisions about approaching eligible patients. Some
oncologists and research nurses described instances where
patients had been deemed eligible by the MDT but were not
approached because of how they presented emotionally at
their appointment, and other instanceswhere patients were
approached with hesitancy, based on judgements about
their ability to cope with trial participation decisions.
So we might, if we thought they weren’t really suitable, we
might say “Well, we do have a trial that would help us to
choose whether to have chemotherapy or not and would
you like us to explain that to you?” in a kind of very general
way, and kind of probably hoping that the patient will say
“No, I don’t want anything like.. oh no I don’t want that.”
(Research Nurse Site 2)
Table 1






Audio-recordings of recruitment discussions between oncologists and patients
Number of audio-recordings Number of patients Number of oncologists
Site 1 1 oncologist*
1 surgeon
1 research nurse
4 2 1 oncologist
Site 2 1 oncologist* 23 11 4 oncologists
Site 3 4 oncologists
1 research nurse
7 5 2 oncologists
Site 4 0 6 5 1 oncologist
Site 5 0 4 4 2 oncologist
Site 6 0 2 2 1 oncologist




Total 14 46 29 11
* Member of the Trial Management Group.
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audio-recorded recruitment discussions revealed how on-
cologists’ communication practices could undermine trial
recruitment, despite their best intentions to recruit.
Applying routine approaches to discussing adjuvant
chemotherapy did not align with the trial’s premise, and
created problems in some cases, as outlined below.
Structure of appointments and conveying chemotherapy
uncertainty
All recruiters successfully mentioned uncertainty around
the benefits of chemotherapy as part of the RCT rationale.
Oncologists generally used one of two approaches to
structuring the discussion: (i) introducing chemotherapy as
a beneficial treatment (as per routine practice), and then
explaining the trial rationale; or (2) introducing the un-
certainties around chemotherapy from the outset of the
consultation, followed by an explanation of the trial. The
first approach sometimes coincided with patients settling
on the idea of needing chemotherapy; to then introduce the
idea that they may not benefit from chemotherapy and
could potentially forego this in OPTIMA Prelim, was there-
fore somewhat confusing.
Oncologist: Back to drugs. The other thing that we have to
consider, and it’s I would say a case of icing on the cake, but
nevertheless, we should talk about it, is the benefits of a
course of chemotherapy.
Patient: Would you recommend it then?
Oncologist: I think with what you have, there is probably
enough benefit for it to be worthwhile. It should be
considered quite seriously.
[Later]
Patient: So without chemotherapy?
Oncologist: There is a bigger risk that this comes back in
the future. It’s not a huge risk, but it’s enough to make the
benefits of chemotherapy worthwhile.Patient: Okay. I’ve got to do it then, haven’t I?
Oncologist: There is a possible way out of this. [Introduces
OPTIMA Prelim and the Oncotype DX test].
Patient: You’ve completely confused me now. OK, so I
accept that I’ve got to have the chemotherapy.
By contrast, opening the discussion with the un-
certainties of chemotherapy benefit provided a smoother
route to explaining the trial rationale.
Oncologist: The thing that is a little harder to decide is
whether you need chemotherapy or not.
Patient: It’s the big one yeah.
Oncologist: It’s a harder decision for two reasons. One is,
that it’s, lots of patients like yourself would be fine even if
they didn’t have it, and also it has obviously more side ef-
fects [explains probability of benefit]. That means though
that 90 of them or more who have had chemotherapy have
had no benefit.
Patient: It’s just whether I’m one of those ones.
Conveying equipoise
Participation in OPTIMA Prelim required patients to be
happy (in principle) with the idea of being allocated ‘current
care’ (chemotherapy) or test-directed treatment, which
carried the possibility that they would not receive chemo-
therapy. As recruiters, oncologists and research nurses
needed to convey equipoise by finely balancing the ad-
vantages and disadvantages of each of the trial arms. One
aspect that proved difficult was addressing uncertainty
about the Oncotype DX test’s effectiveness, which under-
pinned the need for the trial. Oncologists and research
nurses discussed experiences of some patients opting to
access the test outside the National Health Service and
other patients not being comfortable with the uncertainty
around the test. Conveying the potential benefits and dis-
advantages of the test proved a delicate balancing act.
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ments had the potential to tip the balance towards or
against test-directed treatment. Some recruiters reverted
to terms and phrases that would usually be helpful for
explaining the rationale for chemotherapy (in routine
practice), but this undermined the need to convey equi-
poise in the RCT context. For example, referring to
chemotherapy as ‘icing on the cake’ had the potential to
influence a patient’s perception of chemotherapy as a
worthwhile treatment.
Some oncologists continued their routine practice of
referring to online predictor tools (e.g. PREDICT1 and
Adjuvant! Online2) to show likely chemotherapy benefit to
patients, despite the trial’s hypothesis that MPAs provide a
superior framework for decision-making. Some patients
who were shown the graphical representation of possible
chemotherapy benefit interpreted this as definitive indi-
vidual benefit for them, rather than the estimated popula-
tion benefit these tools provide. This contradicted the ethos
of the trial, i.e. examining the effectiveness of MPAs as
predictors for individual patient benefit.
Addressing patients’ preferences and expectations
Oncologists and research nurses anticipated that patient
preferences would be a barrier to recruitment and often
discussed this in terms of patients not wanting to forgo
chemotherapy. The audio-recorded appointments showed
that when preferences were expressed, recruiters tended to
cease discussion about the trial; their accounts in in-
terviews often indicated concern about upsetting the
clinicianepatient relationship.
Well I think it’s quite important not to [respond to a patient
preference], it has the potential to kind of damage the
relationship with the patient because the patient then feels,
there’s risk that they might feel they’re letting you down.
(Oncologist Site 2)
In such instances, patients’ perceptions (and potential
misconceptions) about treatments were not addressed,
resulting in missed opportunities to offer additional in-
formation patients might not have considered. For
example, in one appointment the patient was concerned
about hair loss from chemotherapy, although this only
arose after she had declined the RCT in favour of endocrine
therapy alone. The strategies that some other recruiters
had used to try to inform patients about options available
to address hair loss (e.g. cold capping, wigs) were not
discussed in this instance.
A key issue that was reported in interviews and was
apparent in some recordings was patients’ up-front ex-
pectations for chemotherapy. Some patients reported that
surgeons had referred to chemotherapy as advisable or the
next step in their post-surgical treatment, reflecting the
‘signposting’ that might be offered in routine practice. In1 National Cancer Registration and Analysis ServiceEast Regional Office,
Victoria House, Capital Park, Fulbourn, Cambridge CB21 5XB. Email: info@
predict.nhs.uk.
2 Online e Ajuvant! Inc, San Antonio, TX, USA.the context of OPTIMA Prelim, however, this could make it
very difficult for oncologists to explain the rationale for the
trial.
Relative: ‘Cos e I know, before today, my wife had decided
that she wasn’t going to go on the trial.
Oncologist: OK.
Patient: Um, purely because when I spoke to [Mr X, sur-
geon], my husband asked him what he’d do and he said if it
was his sister, he would highly advise the chemo.Phase 2: developing and delivering a ‘Plan of Action’ to
optimise recruitment
Issues arising from phase 1 were first reported to the
chief investigator/TMG 2 months after the QRI started. The
QRI team worked with the TMG to co-produce a series of
interventions to address recruitment challenges. Table 2
details the interventions and the timing of their imple-
mentation, together with the issues they were designed to
address.
A ‘tips and guidance’ document was drafted and circu-
lated to all sites and provided suggestions for structuring
recruitment consultations, talking about the uncertain
benefits of chemotherapy and discussing the Oncotype DX
test (see Supplementary Material). The QRI researchers and
TMG also revised the Patient Information Sheet to convey a
clearer, more balanced portrayal of the advantages and
disadvantages of using Oncotype DX to determine
chemotherapy.
Individual and group feedback were core components of
the plan of action, enabling the QRI team to use anonymised
extracts from interviews and audio-recorded appointments
to illustrate key recruitment issues and facilitate discussion
around clinician-driven possible solutions. Extracts from
the interviews and audio-recorded appointments illumi-
nated variable views about eligibility criteria and patient
preferences, and the chief investigator/TMG members
contributed expert knowledge to elicit group discussion
and engender peer-to-peer learning. At one session, the
chief investigator used clinical vignettes portraying patients
at the margins of the eligibility criteria to tease out and
address sources of discomfort. Group feedback sessions also
covered issues around structuring consultations, use of
language and the subsequent ways in which these could
influence patients’ interpretation of trial information. In
addition to these group sessions, oncologists who provided
audio-recorded appointments received individual confi-
dential feedback. Issues discussed included structuring the
recruitment discussion by opening with chemotherapy
uncertainty, explaining the study rationale and design, and
strategies for clearly explaining the Oncotype DX test and
RCT concepts.Recruitment outcomes
OPTIMA Prelim exceeded its recruitment target, con-
senting 350 patients and randomising 313 patients in 20
Table 2
OPTIMA Prelim recruitment challenges and corresponding QuinteT Recruitment Intervention (QRI)
QRI action implemented Recruitment issue addressed
Tips and guidance document circulated
to all sites (October 2013)
 Structuring the consultation
 Explaining chemotherapy and its uncertainties
 Talking about the test
Revised Patient Information Sheet distributed
to all sites (October 2013)
 Convey more balanced portrayal of the advantages
and disadvantages of test-directed chemotherapy
Group feedback:
Scottish sites (November 2013)
South West and Welsh sites (January 2014)
Site 5 (March 2014)
Site 6 (March 2014)
 Identifying potentially eligible patients
 Approaching eligible patients
 Discussing the study in recruitment appointments
(conveying uncertainty of chemotherapy, use of chemotherapy
predictor tools, explaining trial concepts, probing patient preferences)
Recruitment tips presented to newly opening
sites (January 2014 onwards)
 Explaining chemotherapy and its uncertainties
Individual recruiter feedback to four oncologists
(February to March 2014)
 Discussing the study in recruitment appointments (as above)
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established its acceptability to patients and clinicians and
secured funding, the main OPTIMA trial (with an integrated
QRI) opened to recruitment in January 2017. The study is
currently recruiting frommore than 100 sites across the UK
and Norway.
Discussion
Our study used the QRI to understand and address the
challenges of recruiting to a de-escalation trial comparing
routine with a novel approach to determining adjuvant
chemotherapy provision in patients with early stage breast
cancer. Despite experiencing challenges, the recruitment
target was eventually exceeded within the funded timescale
through identifying and addressing the root causes of
recruitment difficulties in real-time.We identified numerous
ways in which oncologists’ routine practices could either
subtly or sometimes overtly inhibit RCT recruitment. There
was evidence that some oncologists and MDTs gravitated
towards offering the trial to a kernel of patients within the
wider eligible population, avoiding those with clinical char-
acteristics that they felt indicated a clear need for chemo-
therapy (e.g. greater lymph node involvement). When
patients were approached, terminology and tools typically
used to discuss chemotherapy in routine practicewere found
to contradict the rationale for OPTIMA Prelim and undermine
recruitment. To tackle these challenges, a series of in-
terventions were implemented, including a ‘tips and guid-
ance’ document, individual and group feedback, and
revisions to the Patient Information Sheet.
This study illuminated howoncologists’ routine practices
could inhibit recruitment at multiple stages of the recruit-
ment process. There was evidence that not all clinicians
and/or MDTs felt comfortable offering the study to all
groups of eligible patients, which if widespread and
inconsistently done across sites, might threaten the
external validity of the definitive trial results as applied to
all potentially eligible patients [22]. Discomfort with andselective application of trial eligibility criteria have been
observed in other RCTs, as reported in a cross-trial investi-
gation of recruitment issues across six RCTs that spanned
different medical specialties (including oncology, mental
health and surgery) [11,12]. Airing and addressing these
issues was central to the OPTIMA Prelim ‘plan of action’.
Recruiters were encouraged to consider their own percep-
tions of equipoise through clinical vignettes in group feed-
back sessions, where they had an opportunity to reflect on
their practice and that of their peers and discuss and share
concerns.
OPTIMA Prelim demonstrated the challenges of negoti-
ating ‘current best practices’ in routine care with the
endeavour of improving future patients’ care through their
role as trial recruiters. OPTIMA Prelim and the main trial
have the potential to transform future practice, but this is
counterbalanced by the possibility of significant conse-
quences for current patients should the trial hypothesis not
be supported. Furthermore, although accustomed to
recruiting to trials exploring additional treatments, oncol-
ogists were less familiar recruiting to de-escalation trials
[1,20,21,23,24]. A growing body of work has focussed on
tensions recruiters face when trying to negotiate their
‘clinical’ and ‘research’ roles [11,12,22,25], contributing to
the often ‘hidden’ emotional and intellectual challenges of
recruiting patients [12,13]. Being mindful of the potential
challenges and pitfalls of implementing trial eligibility
criteria may help clinical investigators plan for and identify
these issues more readily. Examining and reflecting on
actual recruitment practices as a trial is underway is a
fundamental part of the QRI and can provide a means of
identifying and working through these trial-specific issues.
Peer-to-peer interactions involving recruiters from
different sites, as facilitated in OPTIMA Prelim through
group feedback sessions, can be particularly helpful for
engaging with these hidden challenges and dissolving
discomforts.
OPTIMA Prelim recruitment, as with many oncology
trials, relied on multidisciplinary professional involvement.
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tially eligible patients. Breast surgeons and specialist nurses
then had the important role of setting patients’ expecta-
tions about adjuvant treatment before a full discussion
about the study with the oncologist. Some surgeons
continued to prepare eligible patients for adjuvant chemo-
therapy during post-surgery consultations, possibly
reflecting a lack of awareness about the trial or equipoise
issues. The importance of a collaborative approach to
recruitment is well established [26e28], particularly in
oncology [29], as is the drive for more holistic team ap-
proaches to recruitment training [30e33]. Our findings
from OPTIMA Prelim support an ongoing need to focus
training and support team ownership of recruitment,
especially with trials that span clinical disciplines.
The study had several limitations. Site participation in
interviews and audio-recording of consultations was
optional and nine of 25 sites participated. It is possible that
participating sites represented more engaged clinicians/
sites; nonetheless, it is notable that even these possibly
more ‘engaged’ sites encountered the recurring challenges
reported in this paper. It is anticipated that less engaged
sites also encountered these issues, with possible other
challenges not captured. Four of the 14 semi-structured
interviews were conducted with TMG members: although
valuable for providing insight into the motivation and ex-
pected conduct of the study, these interviewees may have
skewed the findings, although the issues reported in this
paper were reflective of the general, recurring issues that
arose across the dataset.
Conversely, strengths of the study included the use of
audio-recordings of real recruitment interactions to
examine what actually happens during recruitment dis-
cussions (rather than relying solely on informants’ reported
practices) and the triangulation of multiple methods to
identify the key sources of recruitment difficulty. This
enabled a detailed and robust understanding of recruitment
issues in a relatively short space of time, which allowed the
trial team to develop and implement strategies to address
issues as the trial was underway (rather than towards the
end of an RCT, when it is often too late). The integration of
multiple methods and converging findings lends credibility
to our core findings, although future research should build
on this study to examine whether these novel insights are
relevant in a wider array of RCTs. Further research should
also be invested into the best methods of overcoming the
common challenges recruiters face, including the cost-
effectiveness of training and feedback interventions, such
as the QRI.Conclusion
This was the first study to expose the challenges of
negotiating ‘routine clinical practice’ with clinical trial
recruitment, which is now a core aspect of practising cli-
nicians’ roles. The findings highlight the need to support
clinicians to negotiate their clinical and research roles,
particularly in the context of de-escalation cancer trials.Conflict of Interest
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